

Supplementary Table 1. Immunocompromising conditions and related International Classification of Diseases, 9th and 10th Revision (ICD) discharge codes.

Immunocompromising condition	ICD-10 codes	ICD-9 codes
Solid malignancy		
Organ system malignant tumors	C00*-C80*	140*-199*
Neuroendocrine tumors	C7A*, C7B*, D3A*	209*
Encounter for antineoplastic radiation therapy	Z51.0	V58.0*
Encounter for antineoplastic chemotherapy and immunotherapy	Z51.1*	V58.1*
Hematological malignancy		
Hodgkin lymphoma	C81*	201*
Follicular lymphoma	C82*	202*
Non-follicular lymphoma	C83*	200*
Malignant immunoproliferative diseases and certain other B-cell lymphomas	C88*	203*
Multiple myeloma and malignant plasma cell neoplasms	C90*	203*
Lymphoid leukemia	C91*	204*
Myeloid leukemia	C92*	205*
Monocytic leukemia	C93*	206*
Other leukemias of specified cell type	C94*	207*
Leukemia of unspecified cell type	C95*	208*
Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue	C96*	202*
Constitutional aplastic anemia	D61.0*	284.0*
Idiopathic aplastic anemia	D61.2	284.89
Aplastic anemia, unspecified	D61.9	284.9
Congenital neutropenia	D70.0	288.01
Functional disorders of polymorphuncular neutrophils	D71*	288.1*
Mature T/NK-cell lymphoma	C84*	202.1, 202.2, 202.7, 202.8, 200.6
Other specified and unspecified types of non-Hodgkin lymphoma	C85*	202.8*
Other specified types of T/NK cell lymphoma	C86*	202.8*
Myelodysplastic syndromes	D46*	238.72-238.75
Rheumatologic or inflammatory disorder		
Polyarteritis nodosa and related conditions	M30*	446*
Lupus erythematosus	L93.0*, L93.2*, M32*	695.4*, 710.0
Diffuse connective tissue disease	L94*, M35.8*, M35.9*	710, 710.5, 710.8, 710.9
Rheumatoid arthritis with rheumatoid factor	M05*	
Other rheumatoid arthritis	M06*	
Juvenile arthritis	M08*	714.3*
Sarcoidosis	D86*	135*
Amyloidosis NOS	E85	277.3, 277.30
Amyloidosis NEC	E85.1, E85.3, E85.8*	277.39
Multiple sclerosis	G35*	340*
Allergic alveolitis/pneumonitis NOS	T78.40*, J67.9*	495.9*

Inflammatory spondylopathies	M46*	720*
Polymyalgia rheumatic	M31.5*, M35.3*	725*
Enteropathic arthropathies	M07*	
Wegener's granulomatosis	M31.3*	446.4
Dermatopolymyositis	M33*	710.3, 710.4,
Systemic sclerosis (scleroderma)	M34*	710.1
Psoriatic juvenile arthropathy	L40.54	696.0*
Other psoriatic arthropathy	L40.59	696.0*
Heredofamilial amyloidosis, unspecified	E85.2	277.39
Secondary systemic amyloidosis	E85.4	277.39
Amyloidosis, unspecified	E85.9	277.30
Other intrinsic immune condition or immunodeficiency		
Disorders of immune mechanism	D89	279*
Other specified disorders involve the immune mechanism, not elsewhere classified	D89.8*	279.49, 279.8
Disorder involve the immune mechanism, unspecified	D89.9	279.9
Leukocyte disease NEC	D72.89	288.8
Leukocyte disease NOS	D27.9	288.9
Immunodeficiency with predominantly antibody defects	D80*	279.19
Combined immunodeficiencies	D81	279.2, 279.13
Severe combined immunodeficiency (SCID) with reticular dysgenesis	D81.0	279.2
SCID with low T-and B-cell numbers	D81.1	279.2
SCID with low or normal T-and B-cell numbers	D81.2	279.2
Nezelof's syndrome	D81.4	279.13
Other combined immunodeficiencies	D81.8*	279.2
Combined immunodeficiency, unspecified	D81.9	272.9
Immunodeficiency associated with other major defects	D82*	279.12, D79.11
Common variable immunodeficiency	D83*	279.06, 279.10
Other immunodeficiencies	D84*	277.6, 279*
Other constitutional aplastic anemia	D61.09	284.09
End stage liver disease or equivalent (e.g., cirrhosis, ascities)	K70.3*, K70.4*, K72*, K74.3-K74.6, R18*	571.2, 571.3, 571.5, 571.6, 572*, 789.5*
Nephrotic syndrome	N04*	581*
Purine nucleoside phosphorylase [PNP] deficiency	D81.5	
Major histocompatibility complex class I deficiency	D81.6	279.2
Major histocompatibility complex class II deficiency	D81.7	279.2
Polyclonal hypergammaglobulinemia	D89.0	
Cryoglobulinemia	D89.1	
Immune reconstitution syndrome	D89.3	279.8
Mast cell activation syndrome and related disorders	D89.4*	279.8
Organ or stem cell transplant		
Complications of bone marrow transplant	T86.0	996.85
Complications of kidney transplant	T86.1	
Complications of heart transplant	T86.2	
Complications of heart-lung transplant	T86.3	
Complications of liver transplant	T86.4	

Complications of stem cell transplant	T86.5	996.88
Complications of lung transplant	T86.81	
Complications of intestine transplant	T86.85	
Transplanted organ and tissue status	Z94*	V42*
Transplanted organ removal status	Z98.85	V45.87
Post-transplant lymphoproliferative disorder	D47.Z1	238.77
Encounter for aftercare following organ transplant	Z48.2*	V58.44

*** Includes all sub-codes.**

Supplementary Table 2. Covariates with remaining imbalances between vaccinated and unvaccinated groups after application of inverse propensity-to-be-vaccinated weighting for each vaccine effectiveness estimate, based on an absolute standardized mean or proportion difference ≥ 0.2 .

Vaccinated Exposure Group	Setting	Immunocompromised Status	Other Subgroup Criteria	Covariates with absolute SMD ≥ 0.2 after weighting*
2 mRNA doses (≥ 14 days earlier)	ED/UC	Non-immunocompromised	None	None
2 mRNA doses (14-149 days earlier)	ED/UC	Non-immunocompromised	None	None
2 mRNA doses (≥ 150 days earlier)	ED/UC	Non-immunocompromised	None	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Non-immunocompromised	None	None
2 Moderna doses (≥ 14 days earlier)	ED/UC	Non-immunocompromised	None	None
2 Moderna doses (14-149 days earlier)	ED/UC	Non-immunocompromised	None	None
2 Moderna doses (≥ 150 days earlier)	ED/UC	Non-immunocompromised	None	None
3 Moderna doses (≥ 7 days earlier)	ED/UC	Non-immunocompromised	None	None
2 Pfizer doses (≥ 14 days earlier)	ED/UC	Non-immunocompromised	None	None
2 Pfizer doses (14-149 days earlier)	ED/UC	Non-immunocompromised	None	None
2 Pfizer doses (≥ 150 days earlier)	ED/UC	Non-immunocompromised	None	None
3 Pfizer doses (≥ 7 days earlier)	ED/UC	Non-immunocompromised	None	None
2 mRNA doses (≥ 14 days earlier)	ED/UC	Immunocompromised	None	None
2 mRNA doses (14-149 days earlier)	ED/UC	Immunocompromised	None	None
2 mRNA doses (≥ 150 days earlier)	ED/UC	Immunocompromised	None	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Immunocompromised	None	None
2 Moderna doses (≥ 14 days earlier)	ED/UC	Immunocompromised	None	None
2 Moderna doses (14-149 days earlier)	ED/UC	Immunocompromised	None	None
2 Moderna doses (≥ 150 days earlier)	ED/UC	Immunocompromised	None	None
3 Moderna doses (≥ 7 days earlier)	ED/UC	Immunocompromised	None	Urban-rural classification of facility (SMD=0.20)
2 Pfizer doses (≥ 14 days earlier)	ED/UC	Immunocompromised	None	None
2 Pfizer doses (14-149 days earlier)	ED/UC	Immunocompromised	None	None
2 Pfizer doses (≥ 150 days earlier)	ED/UC	Immunocompromised	None	None
3 Pfizer doses (≥ 7 days earlier)	ED/UC	Immunocompromised	None	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Non-immunocompromised	None	None
2 mRNA doses (14-149 days earlier)	Hospital	Non-immunocompromised	None	None
2 mRNA doses (≥ 150 days earlier)	Hospital	Non-immunocompromised	None	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Non-immunocompromised	None	None
2 Moderna doses (≥ 14 days earlier)	Hospital	Non-immunocompromised	None	None
2 Moderna doses (14-149 days earlier)	Hospital	Non-immunocompromised	None	None
2 Moderna doses (≥ 150 days earlier)	Hospital	Non-immunocompromised	None	None
3 Moderna doses (≥ 7 days earlier)	Hospital	Non-immunocompromised	None	None

Vaccinated Exposure Group	Setting	Immunocompromised Status	Other Subgroup Criteria	Covariates with absolute SMD ≥ 0.2 after weighting*
2 Pfizer doses (≥ 14 days earlier)	Hospital	Non-immunocompromised	None	None
2 Pfizer doses (14-149 days earlier)	Hospital	Non-immunocompromised	None	None
2 Pfizer doses (≥ 150 days earlier)	Hospital	Non-immunocompromised	None	None
3 Pfizer doses (≥ 7 days earlier)	Hospital	Non-immunocompromised	None	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Immunocompromised	None	None
2 mRNA doses (14-149 days earlier)	Hospital	Immunocompromised	None	None
2 mRNA doses (≥ 150 days earlier)	Hospital	Immunocompromised	None	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Immunocompromised	None	None
2 Moderna doses (≥ 14 days earlier)	Hospital	Immunocompromised	None	None
2 Moderna doses (14-149 days earlier)	Hospital	Immunocompromised	None	None
2 Moderna doses (≥ 150 days earlier)	Hospital	Immunocompromised	None	None
3 Moderna doses (≥ 7 days earlier)	Hospital	Immunocompromised	None	None
2 Pfizer doses (≥ 14 days earlier)	Hospital	Immunocompromised	None	None
2 Pfizer doses (14-149 days earlier)	Hospital	Immunocompromised	None	None
2 Pfizer doses (≥ 150 days earlier)	Hospital	Immunocompromised	None	None
3 Pfizer doses (≥ 7 days earlier)	Hospital	Immunocompromised	None	None
2 mRNA doses (≥ 14 days earlier)	ED/UC	Solid malignancy only	None	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Solid malignancy only	None	None
2 mRNA doses (≥ 14 days earlier)	ED/UC	Hematological malignancy only	None	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Hematological malignancy only	None	None
2 mRNA doses (≥ 14 days earlier)	ED/UC	Rheumatologic/inflammatory only	None	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Rheumatologic/inflammatory only	None	None
2 mRNA doses (≥ 14 days earlier)	ED/UC	Other immune disorder only	None	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Other immune disorder only	None	Presence of prior SARS-CoV-2 testing pre-vaccination (SMD=0.27)
2 mRNA doses (≥ 14 days earlier)	ED/UC	Organ/stem cell transplant only	None	Presence of prior SARS-CoV-2 testing pre-vaccination (SMD=0.21)
3 mRNA doses (≥ 7 days earlier)	ED/UC	Organ/stem cell transplant only	None	Race (SMD=0.24)
2 mRNA doses (≥ 14 days earlier)	Hospital	Solid malignancy only	None	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Solid malignancy only	None	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Hematological malignancy only	None	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Hematological malignancy only	None	Presence of prior SARS-CoV-2 testing pre-vaccination (SMD=0.29), ischemic heart disease (SMD=0.24)
2 mRNA doses (≥ 14 days earlier)	Hospital	Rheumatologic/inflammatory only	None	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Rheumatologic/inflammatory only	None	None

Vaccinated Exposure Group	Setting	Immunocompromised Status	Other Subgroup Criteria	Covariates with absolute SMD ≥ 0.2 after weighting*
2 mRNA doses (≥ 14 days earlier)	Hospital	Other immune disorder only	None	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Other immune disorder only	None	Hypertension (SMD=0.22)
2 mRNA doses (≥ 14 days earlier)	Hospital	Organ/stem cell transplant only	None	Presence of prior SARS-CoV-2 testing pre-vaccination (SMD=0.23)
3 mRNA doses (≥ 7 days earlier)	Hospital	Organ/stem cell transplant only	None	Other neurological/musculoskeletal disorder (SMD=0.27)
2 mRNA doses (≥ 14 days earlier)	ED/UC	Immunocompromised, no organ/stem cell transplant	None	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Immunocompromised, no organ/stem cell transplant	None	None
2 Moderna doses (≥ 14 days earlier)	ED/UC	Immunocompromised, no organ/stem cell transplant	None	None
3 Moderna doses (≥ 7 days earlier)	ED/UC	Immunocompromised, no organ/stem cell transplant	None	None
2 Pfizer doses (≥ 14 days earlier)	ED/UC	Immunocompromised, no organ/stem cell transplant	None	None
3 Pfizer doses (≥ 7 days earlier)	ED/UC	Immunocompromised, no organ/stem cell transplant	None	None
2 mRNA doses (≥ 14 days earlier)	ED/UC	Organ/stem cell transplant	None	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Organ/stem cell transplant	None	None
2 Moderna doses (≥ 14 days earlier)	ED/UC	Organ/stem cell transplant	None	None
3 Moderna doses (≥ 7 days earlier)	ED/UC	Organ/stem cell transplant	None	Other neurological/musculoskeletal disorder (SMD=0.20), COPD (SMD=0.22)
2 Pfizer doses (≥ 14 days earlier)	ED/UC	Organ/stem cell transplant	None	None
3 Pfizer doses (≥ 7 days earlier)	ED/UC	Organ/stem cell transplant	None	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Immunocompromised, no organ/stem cell transplant	None	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Immunocompromised, no organ/stem cell transplant	None	None
2 Moderna doses (≥ 14 days earlier)	Hospital	Immunocompromised, no organ/stem cell transplant	None	None
3 Moderna doses (≥ 7 days earlier)	Hospital	Immunocompromised, no organ/stem cell transplant	None	None
2 Pfizer doses (≥ 14 days earlier)	Hospital	Immunocompromised, no organ/stem cell transplant	None	None

Vaccinated Exposure Group	Setting	Immunocompromised Status	Other Subgroup Criteria	Covariates with absolute SMD ≥ 0.2 after weighting*
3 Pfizer doses (≥ 7 days earlier)	Hospital	Immunocompromised, no organ/stem cell transplant	None	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Organ/stem cell transplant	None	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Organ/stem cell transplant	None	None
2 Moderna doses (≥ 14 days earlier)	Hospital	Organ/stem cell transplant	None	None
3 Moderna doses (≥ 7 days earlier)	Hospital	Organ/stem cell transplant	None	Blood disorder (SMD=0.21), other heart disease (SMD=0.21), asthma (SMD=0.24)
2 Pfizer doses (≥ 14 days earlier)	Hospital	Organ/stem cell transplant	None	None
3 Pfizer doses (≥ 7 days earlier)	Hospital	Organ/stem cell transplant	None	Other metabolic disease (SMD=0.25)
2 mRNA doses (≥ 14 days earlier)	ED/UC	Non-immunocompromised	Ages 18-64	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Non-immunocompromised	Ages 18-64	None
2 mRNA doses (≥ 14 days earlier)	ED/UC	Non-immunocompromised	Ages ≥ 65	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Non-immunocompromised	Ages ≥ 65	None
2 mRNA doses (≥ 14 days earlier)	ED/UC	Immunocompromised	Ages 18-64	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Immunocompromised	Ages 18-64	Liver disease (SMD=0.21)
2 mRNA doses (≥ 14 days earlier)	ED/UC	Immunocompromised	Ages ≥ 65	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Immunocompromised	Ages ≥ 65	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Non-immunocompromised	Ages 18-64	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Non-immunocompromised	Ages 18-64	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Non-immunocompromised	Ages ≥ 65	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Non-immunocompromised	Ages ≥ 65	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Immunocompromised	Ages 18-64	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Immunocompromised	Ages 18-64	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Immunocompromised	Ages ≥ 65	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Immunocompromised	Ages ≥ 65	None
2 mRNA doses (≥ 14 days earlier)	ED/UC	Non-immunocompromised	NH White	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Non-immunocompromised	NH White	None
2 mRNA doses (≥ 14 days earlier)	ED/UC	Non-immunocompromised	NH Black	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Non-immunocompromised	NH Black	Chronic non-respiratory condition (SMD=0.25)
2 mRNA doses (≥ 14 days earlier)	ED/UC	Non-immunocompromised	Hispanic	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Non-immunocompromised	Hispanic	None
2 mRNA doses (≥ 14 days earlier)	ED/UC	Immunocompromised	NH White	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Immunocompromised	NH White	None
2 mRNA doses (≥ 14 days earlier)	ED/UC	Immunocompromised	NH Black	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Immunocompromised	NH Black	Liver disease (SMD=0.21), ischemic heart disease (SMD=0.22)

Vaccinated Exposure Group	Setting	Immunocompromised Status	Other Subgroup Criteria	Covariates with absolute SMD ≥ 0.2 after weighting*
2 mRNA doses (≥ 14 days earlier)	ED/UC	Immunocompromised	Hispanic	None
3 mRNA doses (≥ 7 days earlier)	ED/UC	Immunocompromised	Hispanic	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Non-immunocompromised	NH White	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Non-immunocompromised	NH White	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Non-immunocompromised	NH Black	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Non-immunocompromised	NH Black	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Non-immunocompromised	Hispanic	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Non-immunocompromised	Hispanic	Renal disease (SMD=0.25), clinical obesity (SMD=0.21), hypertension (SMD=0.26), other metabolic disease (SMD=0.31)
2 mRNA doses (≥ 14 days earlier)	Hospital	Immunocompromised	NH White	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Immunocompromised	NH White	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Immunocompromised	NH Black	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Immunocompromised	NH Black	None
2 mRNA doses (≥ 14 days earlier)	Hospital	Immunocompromised	Hispanic	None
3 mRNA doses (≥ 7 days earlier)	Hospital	Immunocompromised	Hispanic	Hypertension (SMD=0.21)
1 Janssen dose (≥ 14 days earlier)	ED/UC	Non-immunocompromised	None	None
1 Janssen dose (14-149 days earlier)	ED/UC	Non-immunocompromised	None	None
1 Janssen dose (≥ 150 days earlier)	ED/UC	Non-immunocompromised	None	None
1 Janssen dose plus 2 nd dose any product (≥ 7 days earlier)	ED/UC	Non-immunocompromised	None	Presence of prior SARS-CoV-2 testing pre-vaccination (SMD=0.22)
1 Janssen dose (≥ 14 days earlier)	ED/UC	Immunocompromised	None	None
1 Janssen dose (14-149 days earlier)	ED/UC	Immunocompromised	None	None
1 Janssen dose (≥ 150 days earlier)	ED/UC	Immunocompromised	None	None
1 Janssen dose plus 2 nd dose any product (≥ 7 days earlier)	ED/UC	Immunocompromised	None	Solid malignancy (SMD=0.27), Rheumatologic or inflammatory disorder (SMD=0.22)
1 Janssen dose (≥ 14 days earlier)	Hospital	Non-immunocompromised	None	None
1 Janssen dose (14-149 days earlier)	Hospital	Non-immunocompromised	None	None
1 Janssen dose (≥ 150 days earlier)	Hospital	Non-immunocompromised	None	None
1 Janssen dose plus 2 nd dose any product (≥ 7 days earlier)	Hospital	Non-immunocompromised	None	Heart failure (SMD=0.38), non-respiratory underlying medical condition (SMD=0.36), clinical obesity (SMD=0.30)
1 Janssen dose (≥ 14 days earlier)	Hospital	Immunocompromised	None	None
1 Janssen dose (14-149 days earlier)	Hospital	Immunocompromised	None	None
1 Janssen dose (≥ 150 days earlier)	Hospital	Immunocompromised	None	None

Vaccinated Exposure Group	Setting	Immunocompromised Status	Other Subgroup Criteria	Covariates with absolute SMD ≥ 0.2 after weighting*
1 Janssen dose plus 2 nd dose any product (≥ 7 days earlier)	Hospital	Immunocompromised	None	COPD (SMD=0.35), rheumatologic or inflammatory disorder (SMD=0.21), chronic respiratory condition (SMD=0.33), other metabolic disease (SMD=0.31)

Abbreviations: ED, emergency department; NH, non-Hispanic; SMD, standardized mean or proportion difference; UC, urgent care.

* Covariates considered for inclusion in propensity score models and evaluated for imbalances after inverse propensity-to-be-vaccinated weighting, as relevant, included age, sex, race, ethnicity, Medicaid status, calendar date, geographic region, local SARS-CoV-2 circulation on the day of each medical visit, urban-rural classification of facility, hospital type, number of hospital beds, hospital ownership, chronic respiratory condition, chronic non-respiratory condition, asthma, COPD, other chronic lung disease, heart failure, ischemic heart disease, hypertension, other heart disease, stroke, other cerebrovascular disease, diabetes type 1, diabetes type 2, diabetes due to underlying conditions or other specified diabetes, other metabolic disease (excluding diabetes), clinical obesity, clinical underweight, renal disease, liver disease, blood disorder, dementia, other neurological/musculoskeletal disorder, Down syndrome, HIV/AIDS, solid malignancy, hematological malignancy, rheumatologic or inflammatory disorder, other intrinsic immune disorder or underlying immunodeficiency, organ or stem cell transplant, presence of prior SARS-CoV-2 testing (pre-vaccination, if vaccinated), and prior positive SARS-CoV-2 test result (pre-vaccination, if vaccinated). An absolute SMD ≥ 0.20 indicates a non-negligible difference in variable distributions between events for vaccinated versus unvaccinated patients. All covariates with SMD ≥ 0.20 after weighting were also included in the multivariable logistic regression model for the respective vaccine effectiveness estimate(s) to minimize residual confounding.

Supplementary Table 3. Covariates with remaining imbalances between 3-dose mRNA-vaccinated and 2-dose mRNA-vaccinated groups after application of inverse propensity-to-be-vaccinated weighting for each relative vaccine effectiveness estimate, based on an absolute standardized mean or proportion difference ≥ 0.2 .

3-Dose Vaccinated Exposure Group	2-Dose Vaccinated Referent Group	Setting	Immunocompromised Status	Covariates with absolute SMD ≥ 0.2 after weighting*
3 mRNA doses (≥ 7 days earlier)	2 mRNA doses (≥ 14 days earlier)	ED/UC	Non-immunocompromised	None
3 Moderna doses (≥ 7 days earlier)	2 Moderna doses (≥ 14 days earlier)	ED/UC	Non-immunocompromised	None
3 Pfizer doses (≥ 7 days earlier)	2 Pfizer doses (≥ 14 days earlier)	ED/UC	Non-immunocompromised	None
3 mRNA doses (≥ 7 days earlier)	2 mRNA doses (≥ 14 days earlier)	ED/UC	Immunocompromised	None
3 Moderna doses (≥ 7 days earlier)	2 Moderna doses (≥ 14 days earlier)	ED/UC	Immunocompromised	None
3 Pfizer doses (≥ 7 days earlier)	2 Pfizer doses (≥ 14 days earlier)	ED/UC	Immunocompromised	None
3 mRNA doses (≥ 7 days earlier)	2 mRNA doses (≥ 14 days earlier)	Hospital	Non-immunocompromised	None
3 Moderna doses (≥ 7 days earlier)	2 Moderna doses (≥ 14 days earlier)	Hospital	Non-immunocompromised	None
3 Pfizer doses (≥ 7 days earlier)	2 Pfizer doses (≥ 14 days earlier)	Hospital	Non-immunocompromised	None
3 mRNA doses (≥ 7 days earlier)	2 mRNA doses (≥ 14 days earlier)	Hospital	Immunocompromised	None
3 Moderna doses (≥ 7 days earlier)	2 Moderna doses (≥ 14 days earlier)	Hospital	Immunocompromised	None
3 Pfizer doses (≥ 7 days earlier)	2 Pfizer doses (≥ 14 days earlier)	Hospital	Immunocompromised	None

Abbreviations: ED, emergency department; SMD, standardized mean or proportion difference; UC, urgent care.

* Covariates considered for inclusion in propensity score models and evaluated for imbalances after inverse propensity-to-be-vaccinated weighting, as relevant, included age, sex, race, ethnicity, Medicaid status, calendar date, geographic region, local SARS-CoV-2 circulation on the day of each medical visit, urban-rural classification of facility, hospital type, number of hospital beds, hospital ownership, chronic respiratory condition, chronic non-respiratory condition, asthma, COPD, other chronic lung disease, heart failure, ischemic heart disease, hypertension, other heart disease, stroke, other cerebrovascular disease, diabetes type 1, diabetes type 2, diabetes due to underlying conditions or other specified diabetes, other metabolic disease (excluding diabetes), clinical obesity, clinical underweight, renal disease, liver disease, blood disorder, dementia, other neurological/musculoskeletal disorder, Down syndrome, HIV/AIDS, solid malignancy, hematological malignancy, rheumatologic or inflammatory disorder, other intrinsic immune disorder or underlying immunodeficiency, organ or stem cell transplant, presence of prior SARS-CoV-2 testing (pre-vaccination, if vaccinated), and prior positive SARS-CoV-2 test result (pre-vaccination, if vaccinated). An absolute SMD ≥ 0.20 indicates a non-negligible difference in variable distributions between events for 3-dose mRNA-vaccinated versus 2-dose mRNA-vaccinated patients. All covariates with SMD ≥ 0.20 after weighting were also included in the multivariable logistic regression model for the respective relative vaccine effectiveness estimate(s) to minimize residual confounding.

Supplementary Table 4. mRNA COVID-19 vaccine effectiveness against laboratory-confirmed COVID-19–associated emergency department or urgent care events and hospitalizations among non-immunocompromised and immunocompromised adults, by age group and number of vaccine doses, August–December 2021.

	Emergency department and urgent care events						Hospitalizations					
	Total	No. SARS-CoV-2 negative (col %)	No. SARS-CoV-2 positive (col %)	Proportion SARS-CoV-2 positive (row %)	Unadjusted VE* % (95% CI)	Adjusted VE† % (95% CI)	Total	No. SARS-CoV-2 negative (col %)	No. SARS-CoV-2 positive (col %)	Proportion SARS-CoV-2 positive (row %)	Unadjusted VE* % (95% CI)	Adjusted VE† % (95% CI)
Non-immunocompromised adults‡												
Aged 18-64 years												
Unvaccinated (referent)	79740	52071 (45.8)	27669 (83.4)	34.7	–	–	20621	11862 (47.8)	8759 (92.1)	42.5	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	60631	55331 (48.6)	5300 (16.0)	8.7	82 (81-83)	82 (82-83)	12296	11568 (46.6)	728 (7.7)	5.9	91 (91-92)	91 (91-92)
3 doses (≥7 days earlier)	6551	6340 (5.6)	211 (0.6)	3.2	94 (93-95)	94 (92-95)	1434	1410 (5.7)	24 (0.3)	1.7	98 (97-98)	97 (95-98)
Aged ≥65 years												
Unvaccinated (referent)	14373	8727 (20.0)	5646 (59.6)	39.3	–	–	11785	7270 (24.3)	4515 (68.7)	38.3	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	28915	25349 (58.0)	3566 (37.7)	12.3	78 (77-79)	79 (78-80)	19595	17659 (58.9)	1936 (29.4)	9.9	82 (81-83)	81 (80-83)
3 doses (≥7 days earlier)	9861	9607 (22.0)	254 (2.7)	2.6	96 (95-96)	94 (93-95)	5151	5027 (16.8)	124 (1.9)	2.4	96 (95-97)	95 (93-96)
Immunocompromised adults‡												
Aged 18-64 years												
Unvaccinated (referent)	1903	1482 (42.7)	421 (69.2)	22.1	–	–	3290	2568 (39.4)	722 (72.5)	21.9	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	1710	1556 (44.8)	154 (25.3)	9.0	65 (58-71)	65 (57-72)	3389	3159 (48.4)	230 (23.1)	6.8	74 (70-78)	73 (68-77)
3 doses (≥7 days earlier)	468	435 (12.5)	33 (5.4)	7.0	73 (61-82)	68 (51-79)	841	797 (12.2)	44 (4.4)	5.2	80 (73-86)	69 (54-79)
Aged ≥65 years												
Unvaccinated (referent)	1295	1032 (24.4)	263 (49.6)	20.3	–	–	2542	2006 (19.6)	536 (49.4)	21.1	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	2513	2284 (53.9)	229 (43.2)	9.1	61 (52-68)	69 (62-75)	6246	5771 (56.4)	475 (43.8)	7.6	69 (65-73)	74 (69-77)
3 doses (≥7 days earlier)	959	921 (21.7)	38 (7.2)	4.0	84 (77-89)	80 (70-87)	2535	2461 (24.0)	74 (6.8)	2.9	89 (86-91)	89 (84-92)

Abbreviations: CI, confidence interval; VE, vaccine effectiveness.

*Unadjusted vaccine effectiveness was calculated as $[1 - \text{odds ratio}] \times 100\%$, estimated using a test-negative design.

† Adjusted vaccine effectiveness was calculated as $[1 - \text{odds ratio}] \times 100\%$, estimated using a test-negative design and adjusted for age, geographic region, calendar time, prior positive SARS-CoV-2 test result, and local SARS-CoV-2 circulation on the day of each medical visit, and weighted for patients' inverse propensity to be vaccinated (if the patient was vaccinated) or unvaccinated (if the patient was not vaccinated). Generalized boosted regression trees were used to estimate the propensity to be vaccinated based on sociodemographic characteristics, underlying medical conditions, known prior SARS-CoV-2 infection, and facility or hospital characteristics.

‡ Immunocompromised status was defined by the presence (presumed immunocompromised) or absence (presumed non-immunocompromised) of at least one discharge code from the International Classification of Diseases, 9th and 10th Revisions, for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.

Supplementary Table 5. mRNA COVID-19 vaccine effectiveness against laboratory-confirmed COVID-19–associated emergency department or urgent care events and hospitalizations among non-immunocompromised and immunocompromised adults, by race/ethnicity and number of vaccine doses, August–December 2021.

	Emergency department and urgent care events						Hospitalizations					
	Total	No. SARS-CoV-2 negative (col %)	No. SARS-CoV-2 positive (col %)	Proportion SARS-CoV-2 positive (row %)	Unadjusted VE* % (95% CI)	VE† % (95% CI)	Total	No. SARS-CoV-2 negative (col %)	No. SARS-CoV-2 positive (col %)	Proportion SARS-CoV-2 positive (row %)	Unadjusted VE* % (95% CI)	VE† % (95% CI)
Non-immunocompromised adults‡												
Non-Hispanic white												
Unvaccinated (referent)	57491	36896 (36.4)	20595 (76.8)	35.8	–	–	19882	11592 (32.9)	8290 (80.4)	41.7	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	58706	52799 (52.2)	5907 (22.0)	10.1	80 (79-81)	81 (80-82)	20903	18992 (53.8)	1911 (18.5)	9.1	86 (85-87)	85 (84-86)
3 doses (≥7 days earlier)	11834	11512 (11.4)	322 (1.2)	2.7	95 (94-96)	94 (93-95)	4792	4687 (13.3)	105 (1.0)	2.2	97 (96-97)	96 (95-97)
Non-Hispanic Black												
Unvaccinated (referent)	10883	7569 (52.9)	3314 (84.8)	30.4	–	–	4394	3035 (47.5)	1359 (87.3)	30.9	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	6526	5955 (41.6)	571 (14.6)	8.8	78 (76-80)	78 (76-80)	3137	2944 (46.1)	193 (12.4)	6.2	85 (83-88)	86 (83-88)
3 doses (≥7 days earlier)	813	792 (5.5)	21 (0.5)	2.6	94 (91-96)	90 (84-94)	413	408 (6.4)	5 (0.3)	1.2	97 (93-99)	94 (83-98)
Hispanic												
Unvaccinated (referent)	14865	9804 (41.9)	5061 (81.8)	34.0	–	–	4407	2509 (38.2)	1898 (28.9)	43.1	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	13101	12002 (51.3)	1099 (17.8)	8.4	82 (81-83)	84 (83-86)	3818	3563 (54.2)	255 (3.9)	6.7	91 (89-92)	92 (90-93)
3 doses (≥7 days earlier)	1632	1603 (6.8)	29 (0.5)	1.8	96 (95-98)	96 (93-97)	512	504 (7.7)	8 (0.1)	1.6	98 (96-99)	96 (91-98)
Immunocompromised adults‡												
Non-Hispanic white												
Unvaccinated (referent)	2045	1579 (30.6)	466 (58.4)	22.8	–	–	3737	2897 (26.2)	840 (59.2)	22.5	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	2871	2596 (50.3)	275 (34.5)	9.6	64 (58-69)	68 (61-73)	6370	5876 (53.1)	494 (34.8)	7.8	71 (67-74)	72 (68-75)

3 doses (≥ 7 days earlier)	1041	984 (19.1)	57 (7.1)	5.5	80 (74-85)	70 (57-79)	2374	2288 (20.7)	86 (6.1)	3.6	87 (84-90)	82 (76-87)
Non-Hispanic Black												
Unvaccinated (referent)	463	396 (43.0)	67 (68.4)	14.5	–	–	760	625 (34.6)	135 (63.7)	17.8	–	–
Any mRNA vaccine												
2 doses (≥ 14 days earlier)	452	426 (46.3)	26 (26.5)	5.8	64 (42-78)	66 (41-80)	1013	948 (52.5)	65 (30.7)	6.4	68 (57-77)	73 (62-82)
3 doses (≥ 7 days earlier)	104	99 (10.7)	5 (5.1)	4.8	70 (24-88)	55 (–65-88)	245	233 (12.9)	12 (5.7)	4.9	76 (56-87)	82 (56-92)
Hispanic												
Unvaccinated (referent)	456	356 (35.5)	100 (63.7)	21.9	–	–	800	637 (29.4)	163 (59.5)	20.4	–	–
Any mRNA vaccine												
2 doses (≥ 14 days earlier)	551	501 (49.9)	50 (31.8)	9.1	64 (49-75)	69 (51-81)	1252	1156 (53.4)	96 (35.0)	7.7	68 (57-75)	70 (58-78)
3 doses (≥ 7 days earlier)	154	147 (14.6)	7 (4.5)	4.5	83 (63-92)	87 (56-96)	387	372 (17.2)	15 (5.5)	3.9	84 (73-91)	82 (65-91)

Abbreviations: CI, confidence interval; VE, vaccine effectiveness.

*Unadjusted vaccine effectiveness was calculated as $[1 - \text{odds ratio}] \times 100\%$, estimated using a test-negative design.

† Adjusted vaccine effectiveness was calculated as $[1 - \text{odds ratio}] \times 100\%$, estimated using a test-negative design and adjusted for age, geographic region, calendar time, prior positive SARS-CoV-2 test result, and local SARS-CoV-2 circulation on the day of each medical visit, and weighted for patients' inverse propensity to be vaccinated (if the patient was vaccinated) or unvaccinated (if the patient was not vaccinated). Generalized boosted regression trees were used to estimate the propensity to be vaccinated based on sociodemographic characteristics, underlying medical conditions, known prior SARS-CoV-2 infection, and facility or hospital characteristics.

‡ Immunocompromised status was defined by the presence (presumed immunocompromised) or absence (presumed non-immunocompromised) of at least one discharge code from the International Classification of Diseases, 9th and 10th Revisions, for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.

Supplementary Table 6. Characteristics of emergency department and urgent care events among non-immunocompromised and immunocompromised adults with COVID-19–like illness who received the Janssen (Ad26.COV2) COVID-19 vaccine as their first dose, VISION Network, 10 states, August–December 2021.

	Non-immunocompromised adults*	Immunocompromised adults*
	n (column %)	n (column %)
All ED/UC events	9,833 (100)	496 (100)
Site		
Baylor Scott & White Health	1,034 (10.5)	163 (32.9)
Columbia University†	182 (1.8)	31 (6.2)
HealthPartners†	364 (3.7)	9 (1.8)
Intermountain Healthcare	3,139 (31.9)	132 (26.6)
Kaiser Permanente Northern California	2,179 (22.2)	49 (9.9)
Kaiser Permanente Northwest	913 (9.3)	82 (16.5)
Regenstrief Institute	1,443 (14.7)	26 (5.2)
University of Colorado	579 (5.9)	4 (0.8)
Age group, years		
18-49	4,664 (47.4)	101 (20.4)
50-64	2,928 (29.8)	184 (37.1)
65-74	1,211 (12.3)	132 (26.6)
75-84	678 (6.9)	60 (12.1)
≥85	352 (3.6)	19 (3.8)
Sex		
Male	4,291 (43.6)	246 (49.6)
Female	5,542 (56.4)	250 (50.4)
Race/ethnicity		
White, non-Hispanic	6,523 (66.3)	341 (68.7)
Black, non-Hispanic	857 (8.7)	63 (12.7)
Hispanic	1,353 (13.8)	58 (11.7)
Other, non-Hispanic‡	573 (5.8)	19 (3.8)
Unknown	527 (5.4)	15 (3.0)
Chronic respiratory condition§		
Yes	1,936 (19.7)	252 (50.8)
No	7,897 (80.3)	244 (49.2)
Number of doses 		
One Janssen dose	9,179 (93.3)	465 (93.7)
Two doses (any product as second dose)	654 (6.6)	31 (6.2)
mRNA vaccine as second dose	440 (4.5)	24 (4.8)
Janssen vaccine as second dose	214 (2.2)	7 (1.4)

Abbreviations: ED, emergency department; UC, urgent care.

* Immunocompromised status at medical events was defined by the presence (presumed immunocompromised) or absence (presumed non-immunocompromised) of at least one discharge code from the International Classification of Diseases, 9th and 10th Revisions, for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.

† ED data at Columbia University Irving Medical Center and HealthPartners exclude encounters that were transferred to an inpatient setting.

‡ Other race includes Asian, Native Hawaiian, or other Pacific islander, American Indian or Alaska Native, other not listed, and multiple races.

§ Chronic respiratory condition at discharge was defined as the presence of discharge codes from the International Classification of Diseases, 9th and 10th Revisions, for asthma, chronic obstructive pulmonary disease, or other lung disease.

|| Patients who received the Janssen vaccine as their first dose were classified according to receipt of the first in a 1-dose series ≥ 14 days before the medical event index date or the second dose (any product) in a 2-dose series ≥ 7 days before the index date. Patients who received two doses were further classified based on whether the second dose received was an mRNA vaccine or a second dose of the Janssen vaccine.

Supplementary Table 7. Characteristics of hospitalizations among non-immunocompromised and immunocompromised adults with COVID-19–like illness who received the Janssen (Ad26.COV2) COVID-19 vaccine as their first dose, VISION Network, 10 states, August–December 2021.

	Non-immunocompromised adults*	Immunocompromised adults*
	n (column %)	n (column %)
All hospitalizations	3,234 (100)	968 (100)
Site		
Baylor Scott & White Health	518 (16.0)	175 (18.1)
Columbia University	138 (4.3)	55 (5.7)
HealthPartners	45 (1.4)	18 (1.9)
Intermountain Healthcare	334 (10.3)	64 (6.6)
Kaiser Permanente Northern California	968 (29.9)	342 (35.3)
Kaiser Permanente Northwest	191 (5.9)	58 (6.0)
Regenstrief Institute	727 (22.5)	131 (13.5)
University of Colorado	313 (9.7)	125 (12.9)
Age group, years		
18-49	724 (22.4)	142 (14.7)
50-64	1076 (33.3)	396 (40.9)
65-74	665 (20.5)	241 (24.9)
75-84	464 (14.3)	131 (13.5)
≥85	305 (9.4)	58 (6.0)
Sex		
Male	1555 (48.1)	501 (51.8)
Female	1679 (51.9)	467 (48.2)
Race/ethnicity		
White, non-Hispanic	2046 (63.3)	630 (65.0)
Black, non-Hispanic	422 (13.0)	114 (11.8)
Hispanic	431 (13.3)	131 (13.5)
Other, non-Hispanic†	171 (5.3)	63 (6.5)
Unknown	164 (5.1)	30 (3.1)
Chronic respiratory condition‡		
Yes	2106 (65.1)	638 (65.9)
No	1128 (34.9)	330 (34.1)
Number of doses§		
One Janssen dose	3028 (93.6)	920 (95.0)
Two doses (any product as second dose)	206 (6.4)	48 (5.0)
mRNA vaccine as second dose	129 (4.0)	33 (3.4)
Janssen vaccine as second dose	77 (2.4)	15 (1.5)

* Immunocompromised status at hospitalizations was defined by the presence (presumed immunocompromised) or absence (presumed non-immunocompromised) of at least one discharge code from the International Classification of Diseases, 9th and 10th Revisions, for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.

† Other race includes Asian, Native Hawaiian, or other Pacific islander, American Indian or Alaska Native, other not listed, and multiple races.

‡ Chronic respiratory condition at discharge was defined as the presence of discharge codes from the International Classification of Diseases, 9th and 10th Revisions, for asthma, chronic obstructive pulmonary disease, or other lung disease.

§ Patients who received the Janssen vaccine as their first dose were classified according to receipt of the first in a 1-dose series ≥14 days before the hospitalization index date or the second dose (any product) in a 2-dose series ≥7 days before the index date. Patients who received two doses were further classified based on whether the second dose received was an mRNA vaccine or a second dose of the Janssen vaccine.

Supplementary Table 8. Janssen (Ad26.COV2) COVID-19 vaccine effectiveness against laboratory-confirmed COVID-19–associated emergency department or urgent care events and hospitalizations among non-immunocompromised and immunocompromised adults, by number of vaccine doses, August–December 2021.

	Emergency department or urgent care events						Hospitalizations					
	Total	No. SARS-CoV-2 negative (col %)	No. SARS-CoV-2 positive (col %)	Proportion SARS-CoV-2 positive (row %)	Unadjusted VE* % (95% CI)	Adjusted VE† % (95% CI)	Total	No. SARS-CoV-2 negative (col %)	No. SARS-CoV-2 positive (col %)	Proportion SARS-CoV-2 positive (row %)	Unadjusted VE* % (95% CI)	Adjusted VE† % (95% CI)
Non-immunocompromised‡												
Unvaccinated (ref)	94113	60798 (87.9)	33315 (95.7)	35.4	–	–	32406	19132 (87.3)	13274 (96.7)	41.0	–	–
1 Janssen dose (≥14 days earlier)	9179	7733 (11.2)	1446 (4.2)	15.8	66 (64-68)	64 (61-66)	3028	2580 (11.8)	448 (3.3)	14.8	75 (72-77)	72 (69-76)
1 Janssen dose (14-149 days earlier)	2720	2297 (3.3)	423 (1.2)	15.6	66 (63-70)	67 (63-71)	945	824 (3.8)	121 (0.9)	12.8	79 (74-83)	77 (71-82)
1 Janssen dose (≥150 days earlier)	6459	5436 (7.9)	1023 (2.9)	15.8	66 (63-68)	62 (58-65)	2083	1756 (8.0)	327 (2.4)	15.7	73 (70-76)	69 (65-73)
2 doses, 1 Janssen dose plus 2 nd dose any product (≥7 days earlier)	654	620 (0.9)	34 (0.1)	5.2	90 (86-93)	90 (86-93)	206	196 (0.9)	10 (0.1)	4.8	93 (86-96)	93 (86-96)
Immunocompromised‡												
Unvaccinated (ref)	3198	2514 (85.6)	684 (90.4)	21.4	–	–	5832	4574 (84.0)	1258 (92.7)	21.6	–	–
1 Janssen dose (≥14 days earlier)	465	395 (13.4)	70 (9.2)	15.1	35 (15-50)	7 (-26-31)	920	826 (15.2)	94 (6.9)	10.2	59 (48-67)	45 (29-57)
1 Janssen dose (14-149 days earlier)	121	107 (3.6)	14 (1.8)	11.6	52 (16-73)	9 (-66-50)	238	211 (3.9)	27 (2.0)	11.3	53 (30-69)	35 (-3-60)
1 Janssen dose (≥150 days earlier)	344	288 (9.8)	56 (7.4)	16.3	29 (4-47)	-6 (-49-25)	682	615 (11.3)	67 (4.9)	9.8	60 (49-69)	43 (23-58)
2 doses, 1 Janssen dose plus 2 nd dose any product (≥7 days earlier)	31	28 (0.9)	3 (0.4)	9.7	61 (-30-88)	71 (6-91)	48	43 (0.8)	5 (0.4)	10.4	58 (-7-83)	70 (25-88)

Abbreviations: CI, confidence interval; VE, vaccine effectiveness.

*Unadjusted vaccine effectiveness was calculated as $[1 - \text{odds ratio}] \times 100\%$, estimated using a test-negative design.

† Adjusted vaccine effectiveness was calculated as $[1 - \text{odds ratio}] \times 100\%$, estimated using a test-negative design and adjusted for age, geographic region, calendar time, prior positive SARS-CoV-2 test result, and local SARS-CoV-2 circulation on the day of each medical visit, and weighted for patients' inverse propensity to be vaccinated (if the patient was vaccinated) or unvaccinated (if the patient was not vaccinated). Generalized boosted regression trees were used to estimate the propensity to be vaccinated based on sociodemographic characteristics, underlying medical conditions, known prior SARS-CoV-2 infection, and facility or hospital characteristics.

‡ Immunocompromised status was defined by the presence (presumed immunocompromised) or absence (presumed non-immunocompromised) of at least one discharge code from the International Classification of Diseases, 9th and 10th Revisions, for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.